DRUG ERUPTION CAUSED BY RECOMBINANT HUMAN G-CSF

Two types of recombinant human granulocyte colony-stimulating factor ( rhG-CSF) are available, and equally used for mitigation of neutropenia . One is a glycosylated natural product from mammalian cells, and the other a non-glycosylated form from Escherichia coli. Though only minim al adverse effects have been reported for both, we treated two patient s with rhG-CSF-induced systemic eruption. Based on these patients, the following should be noted: 1) drug eruption may occur in both types o f rhG-CSF without detectable antibodies, 2) intradermal test is useful for determination of the causal drug, and 3) if one rhG-CSF product c auses eruption, the alternative one may possibly be safe and effective .